Maryland Attorney General Anthony G. Brown has joined a multistate coalition of 24 Attorneys General in protecting access to abortion medication nationwide. The coalition filed an amicus brief in the U.S. Supreme Court in support of the U.S. Food and Drug Administration’s (FDA) and Danco Laboratories LLC’s petitions to reverse the U.S. Court of Appeals for the Fifth Circuit’s ruling that reinstated certain medically unnecessary, and previously eliminated, restrictions on the medication.
Mifepristone is the only FDA-approved abortion medication, and the coalition argues that the Fifth Circuit’s ruling has dangerous consequences on reproductive health care outcomes, particularly for low-income and underserved communities.
“Our fight to ensure equal access to safe, effective abortion medication, which includes mifepristone, continues,” said Attorney General Brown. “Restricting the availability of mifepristone will harm people who have no other options for safe and affordable abortion.”
The coalition is urging the Supreme Court to grant the petitions to bring the case on medication abortion before the court. The coalition also asks the Supreme Court to reverse the Fifth Circuit’s decision that restricts how mifepristone can be prescribed and dispensed. The brief highlights that the Fifth Circuit’s decision ignores decades of high-quality evidence and clinical research that shows mifepristone is safe and effective.
The coalition notes that if the Fifth Circuit’s decision is permitted to take effect, it could disrupt access to the most common method of abortion, harming countless individuals in need of abortion care or management of pregnancy loss, with widespread implications for the healthcare system. Among other things, the ruling could lead many individuals to undergo procedural abortion, push abortion procedures later in pregnancy, drive up risks, costs, and delays, and deprive many individuals of access to reproductive health care altogether. The coalition further argues that the ruling would create widespread confusion among providers, distributers, and pharmacies, and radically destabilize the regulatory process for drug approvals, stifling scientific innovation and imperiling the development and availability of thousands of drugs nationwide.
In submitting the brief, Attorney General Brown joins the Attorneys General of Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Hawaii, Illinois, Maine, Massachusetts, Michigan, Minnesota, Nevada, New Jersey, New Mexico, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, Vermont, Washington, and Wisconsin.